SCHEMBL97400

SCHEMBL97400

[CH2]c1ccc(C(=O)Nc2ccccc2SC)cc1

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 3/20 0.68
TP53 P04637 3/20 0.68
NPSR1 Q6W5P4 1/20 0.68
HSD17B10 Q99714 1/20 0.68
ALDH1A1 P00352 6/20 0.65
MAPT P10636 2/20 0.65
L3MBTL1 Q9Y468 2/20 0.58
ALOX15 P16050 1/20 0.58
HTT P42858 1/20 0.58
RAB9A P51151 3/20 0.55
NPC1 O15118 1/20 0.55
TDP1 Q9NUW8 2/20 0.55
MAPK1 P28482 1/20 0.54
HDAC1 Q13547 1/20 0.53
HDAC8 Q9BY41 1/20 0.53
HDAC6 Q9UBN7 1/20 0.53
TSHR P16473 1/20 0.52
MDM4 O15151 1/20 0.52
MDM2 Q00987 1/20 0.52
MEN1 O00255 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28189189 0.86 KMT2A (0.76) KMT2ATP53NPSR1HSD17B10ALDH1A1
SCHEMBL28278988 0.85 L3MBTL1 (0.73) KMT2ATP53NPSR1HSD17B10ALDH1A1
SCHEMBL28399871 0.85 KMT2A (0.69) KMT2ATP53NPSR1HSD17B10ALDH1A1
SCHEMBL23657637 0.84 HDAC1 (0.72) KMT2ATP53NPSR1HSD17B10ALDH1A1
SCHEMBL28349237 0.84 TP53 (0.68) KMT2ATP53NPSR1HSD17B10ALDH1A1
SCHEMBL28346556 0.84 KMT2A (0.72) KMT2ATP53NPSR1HSD17B10ALDH1A1
SCHEMBL28348690 0.84 KMT2A (0.68) KMT2ATP53NPSR1HSD17B10ALDH1A1
SCHEMBL28403540 0.81 F10 (0.77) KMT2ATP53NPSR1HSD17B10ALDH1A1
SCHEMBL28277563 0.81 KMT2A (0.64) KMT2ATP53NPSR1HSD17B10ALDH1A1
SCHEMBL28277560 0.81 KMT2A (0.68) KMT2ATP53NPSR1HSD17B10ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8362252-B2 Carbostyril compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-01-29 US disclosed
EP-1797082-B1 CARBOSTYRIL COMPOUND OTSUKA PHARMA CO LTD (JP) 2012-08-29 EP disclosed
EP-2426128-A1 Carbostyril compound Otsuka Pharmaceutical Co., Limited (JP) 2012-03-07 EP disclosed
US-20100261705-A1 CARBOSTYRIL COMPOUND OTSUKA PHARMACEUTICAL CO., LTD. 2010-10-14 US disclosed
US-7777038-B2 Carbostyril compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2010-08-17 US disclosed
US-20090326008-A1 NF-kappa B Inhibitor OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2009-12-31 US disclosed
EP-2043644-A1 NF- B INHIBITOR Otsuka Pharmaceutical Co., Ltd. (JP) 2009-04-08 EP disclosed
WO-2007119600-A9 CARBAZOLE COMPOUND OTSUKA PHARMA CO LTD (JP) 2008-05-02 WO disclosed
WO-2008010601-A1 NF- ϰB INHIBITOR OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2008-01-24 WO disclosed
WO-2007119600-A1 CARBAZOLE COMPOUND OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-10-25 WO disclosed
US-20070179173-A1 Carbostyril compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-02 US disclosed
EP-1797082-A1 CARBOSTYRIL COMPOUND Otsuka Pharmaceutical Company, Limited (JP) 2007-06-20 EP disclosed
WO-2006035954-A1 CARBOSTYRIL COMPOUND OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-04-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090326008-A1 NF-kappa B Inhibitor NFKBIA, NFKB2, IKBKB KMT2A 1059/4885TP53 3154/4885NPSR1 1479/4885
US-20070179173-A1 Carbostyril compound GTF2F1, F3, GTF2F2 KMT2A 2732/4885TP53 1280/4885NPSR1 2023/4885
US-20100261705-A1 CARBOSTYRIL COMPOUND GTF2F1, F3, GTF2F2 KMT2A 2732/4885TP53 1280/4885NPSR1 2023/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.